Clinical Trial Update: Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating differential effects of SGLT2 inhibitors and GLP-1 receptor agonists on beta cell function in Type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GLP-1 receptor agonists
• SGLT2 inhibitors (SGLT2 inhibitor)

Snippet

Sponsor: MaryAnn Banerji | Conditions: Type 2 Diabetes (T2DM) | Phase 4 | Status: ACTIVE_NOT_RECRUITING